The CSL (ASX:CSL) share price is up 6% since earnings result

It's been a good couple of weeks on the ASX for the global biotech company

| More on:
rising medical asx share price represented by excited doctors dancing in ward

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has pushed almost 6% ahead following the release of the company's full-year results.

This comes after the global biotech company recorded another robust performance despite navigating through challenging conditions brought on by the Covid-19 pandemic.

At Monday's market close, the CSL share price finished the day slightly down 0.24% to $310.30. It's worth noting the company's share price is just 3.2% short of its 52-week high achieved in November 2020.

What did CSL report?

A little more than a week ago, CSL provided investors with a detailed update on its business operations. The CSL share price initially dipped on the announcement but has since recovered to push higher.

The company noted that its CSL Behring's portfolio faced headwinds, while its Seqirus business recorded strong tailwinds in FY21. The latter deals in seasonal influenza vaccines.

Under the CSL Behring banner, sales of its leading subcutaneous immunoglobulin product, Hizentra, grew 15%. In addition, sales of hereditary angioedema product, Haegarda, lifted 15%. This contributed to overall revenue of US$8.8 billion for the CSL Behring portfolio, up 6% on FY20.

CSL's Seqirus business experienced a strong surge in seasonal influenza vaccines, up 41%. A record volume of around 130 million doses was distributed around the world. As a whole, Seqirus revenue jumped to US$1.7 billion, up 30% from the prior corresponding period.

In other news possibly affecting the CSL share price, investors were updated on the company's plasma collection issues.

The company noted that federal government stimulus packages from early 2021 had driven down the number of donors per week. This momentarily affected plasma levels before soaring again on the back of vaccine momentum, further marketing initiatives, and a "stimulus burn-off".

As such, plasma collection numbers are down around 20% compared to FY20's levels.

CSL also opened 25 new facilities to attract lapsed and new donors through its doors. In FY22, the company plans to open another 40 centres, expanding its presence, mostly across the United States.

CSL CEO Paul Perreault commented:

Plasma collections are expected to continue improving following multiple initiatives we have implemented. Together with the global rollout of COVID-19 vaccines I'm optimistic of a global recovery with greater social mobility and more normalised conditions.

CSL share price summary

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, but are up 8%. It appears investors believe the worst is over for the company, with vaccination rates climbing and countries eyeing a post-COVID-19 world.

In early trade today, the CSL share price is up 0.53% to $311.94.

On valuation grounds, CSL is the second-largest company on the ASX with a market capitalisation of roughly $141.22 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »